Philogen S.p.a.

Other

L. Molenti & C. Dei Fratelli Alitti Societa' Di Esercizio Societa' Per

Giovanni Neri

Dario Neri

Alessandra Villa

Christoph Rosli

Jascha-Nikolai Rybak

Kathrin Schwager

Jianqing Chen

Melanie C Ruzek

Camilla Bacci

Gabrio Roncucci

Denise M O'Hara

Denise M O'hara

Jascha Nikolai Rybak

Melanie Ruzek

Christoph Roesli

Jascha Rybak

Denise O'HARA

Christoph Rösli

Denise O'hara

This invention relates to stable formulations that can be prepared to high concentration of active agent using low amounts of detergents and to methods for producing such formulations. In particular, this invention relates to formulations containing the L19-TNFα immunocytokine.

Antibody compositions

This invention relates to stable formulations that can be prepared to high concentration of active agent using low amounts of detergents and to methods for producing such formulations. In particular, this invention relates to formulations containing the L19-TNF&#x3b1; immunocytokine.

Specific binding members that bind the ED-A isoform of fibronectin for use in methods of treatment, diagnosis, detection and/or imaging of inflammatory bowel disease (IBD), and/or for use in delivery to the IBD tissue of a molecule conjugated to the specific binding member. The specific binding member may, for example, be conjugated to an immunosupressive or anti-inflammatory molecule, such as interleukin-10.

Anti-ED-A immunoconjugates for inflammatory bowel disease

The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the treatment of tumour metastases.

Antigen associated with the neovasculature of tumour metastases

The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the treatment of tumor metastases.

Conjugated terthiophene and furan compounds with photoenhanced biocidal

Growing community of inventors

Siena, Italy

Giovanni Neri